Literature DB >> 24528109

Identification of specific ligand-receptor interactions that govern binding and cooperativity of diverse modulators to a common metabotropic glutamate receptor 5 allosteric site.

Karen J Gregory1, Elizabeth D Nguyen, Chrysa Malosh, Jeffrey L Mendenhall, Jessica Z Zic, Brittney S Bates, Meredith J Noetzel, Emma F Squire, Eric M Turner, Jerri M Rook, Kyle A Emmitte, Shaun R Stauffer, Craig W Lindsley, Jens Meiler, P Jeffrey Conn.   

Abstract

A common metabotropic glutamate receptor 5 (mGlu5) allosteric site is known to accommodate diverse chemotypes. However, the structural relationship between compounds from different scaffolds and mGlu5 is not well understood. In an effort to better understand the molecular determinants that govern allosteric modulator interactions with mGlu5, we employed a combination of site-directed mutagenesis and computational modeling. With few exceptions, six residues (P654, Y658, T780, W784, S808, and A809) were identified as key affinity determinants across all seven allosteric modulator scaffolds. To improve our interpretation of how diverse allosteric modulators occupy the common allosteric site, we sampled the wealth of mGlu5 structure-activity relationship (SAR) data available by docking 60 ligands (actives and inactives) representing seven chemical scaffolds into our mGlu5 comparative model. To spatially and chemically compare binding modes of ligands from diverse scaffolds, the ChargeRMSD measure was developed. We found a common binding mode for the modulators that placed the long axes of the ligands parallel to the transmembrane helices 3 and 7. W784 in TM6 not only was identified as a key NAM cooperativity determinant across multiple scaffolds, but also caused a NAM to PAM switch for two different scaffolds. Moreover, a single point mutation in TM5, G747V, altered the architecture of the common allosteric site such that 4-nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (VU29) was noncompetitive with the common allosteric site. Our findings highlight the subtleties of allosteric modulator binding to mGlu5 and demonstrate the utility in incorporating SAR information to strengthen the interpretation and analyses of docking and mutational data.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24528109      PMCID: PMC3990945          DOI: 10.1021/cn400225x

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  48 in total

1.  Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.

Authors:  Jeffrey Roppe; Nicholas D Smith; Dehua Huang; Lida Tehrani; Bowei Wang; Jeffrey Anderson; Jesse Brodkin; Janice Chung; Xiaohui Jiang; Christopher King; Benito Munoz; Mark A Varney; Petpiboon Prasit; Nicholas D P Cosford
Journal:  J Med Chem       Date:  2004-09-09       Impact factor: 7.446

2.  Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu₅): from an artificial neural network virtual screen to an in vivo tool compound.

Authors:  Ralf Mueller; Eric S Dawson; Jens Meiler; Alice L Rodriguez; Brian A Chauder; Brittney S Bates; Andrew S Felts; Jeffrey P Lamb; Usha N Menon; Sataywan B Jadhav; Alexander S Kane; Carrie K Jones; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn; Christopher M Olsen; Danny G Winder; Kyle A Emmitte; Craig W Lindsley
Journal:  ChemMedChem       Date:  2012-01-20       Impact factor: 3.466

3.  Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP.

Authors:  Pari Malherbe; Nicole Kratochwil; Andreas Mühlemann; Marie-Thérèse Zenner; Christophe Fischer; Martin Stahl; Paul R Gerber; Georg Jaeschke; Richard H P Porter
Journal:  J Neurochem       Date:  2006-07       Impact factor: 5.372

4.  3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure in rats.

Authors:  Andrew S Felts; Stacey R Lindsley; Jeffrey P Lamb; Alice L Rodriguez; Usha N Menon; Satyawan Jadhav; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley; Kyle A Emmitte
Journal:  Bioorg Med Chem Lett       Date:  2010-06-15       Impact factor: 2.823

5.  Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM.

Authors:  Douglas J Sheffler; Cody J Wenthur; Joshua A Bruner; Sheridan J S Carrington; Paige N Vinson; Kiran K Gogi; Anna L Blobaum; Ryan D Morrison; Mitchell Vamos; Nicholas D P Cosford; Shaun R Stauffer; J Scott Daniels; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2012-04-30       Impact factor: 2.823

6.  The Implication of the First Agonist Bound Activated GPCR X-ray Structure on GPCR in Silico Modeling.

Authors:  Christofer S Tautermann; Alexander Pautsch
Journal:  ACS Med Chem Lett       Date:  2011-03-31       Impact factor: 4.345

7.  Design and synthesis of substituted N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides as positive allosteric modulators of the metabotropic glutamate receptor subtype 5.

Authors:  Mu-Fa Zou; Jianjing Cao; Alice L Rodriguez; P Jeffrey Conn; Amy Hauck Newman
Journal:  Bioorg Med Chem Lett       Date:  2010-12-28       Impact factor: 2.823

8.  A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.

Authors:  Gene G Kinney; Julie A O'Brien; Wei Lemaire; Maryann Burno; Denise J Bickel; Michelle K Clements; Tsing-Bau Chen; David D Wisnoski; Craig W Lindsley; Philip R Tiller; Sheri Smith; Marlene A Jacobson; Cyrille Sur; Mark E Duggan; Douglas J Pettibone; P Jeffrey Conn; David L Williams
Journal:  J Pharmacol Exp Ther       Date:  2004-12-17       Impact factor: 4.030

Review 9.  Metabotropic glutamate receptors: physiology, pharmacology, and disease.

Authors:  Colleen M Niswender; P Jeffrey Conn
Journal:  Annu Rev Pharmacol Toxicol       Date:  2010       Impact factor: 13.820

10.  N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.

Authors:  K J Gregory; E J Herman; A J Ramsey; A S Hammond; N E Byun; S R Stauffer; J T Manka; S Jadhav; T M Bridges; C D Weaver; C M Niswender; T Steckler; W H Drinkenburg; A Ahnaou; H Lavreysen; G J Macdonald; J M Bartolomé; C Mackie; B J Hrupka; M G Caron; T L Daigle; C W Lindsley; P J Conn; C K Jones
Journal:  J Pharmacol Exp Ther       Date:  2013-08-21       Impact factor: 4.030

View more
  19 in total

Review 1.  Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias.

Authors:  K Sengmany; K J Gregory
Journal:  Br J Pharmacol       Date:  2015-11-11       Impact factor: 8.739

Review 2.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

3.  Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.

Authors:  Kathy Sengmany; Junaid Singh; Gregory D Stewart; P Jeffrey Conn; Arthur Christopoulos; Karen J Gregory
Journal:  Neuropharmacology       Date:  2016-07-05       Impact factor: 5.250

4.  Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5.

Authors:  Angela Arsova; Thor C Møller; Line Vedel; Jakob Lerche Hansen; Simon R Foster; Karen J Gregory; Hans Bräuner-Osborne
Journal:  Mol Pharmacol       Date:  2020-05-01       Impact factor: 4.436

5.  Molecular Insights into Metabotropic Glutamate Receptor Allosteric Modulation.

Authors:  Karen J Gregory; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2015-03-25       Impact factor: 4.436

6.  Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles.

Authors:  Jerri M Rook; Mohammed N Tantawy; Mohammad S Ansari; Andrew S Felts; Shaun R Stauffer; Kyle A Emmitte; Robert M Kessler; Colleen M Niswender; J Scott Daniels; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn
Journal:  Neuropsychopharmacology       Date:  2014-09-22       Impact factor: 7.853

Review 7.  Computational modeling of membrane proteins.

Authors:  Julia Koehler Leman; Martin B Ulmschneider; Jeffrey J Gray
Journal:  Proteins       Date:  2014-11-19

8.  Molecular determinants of positive allosteric modulation of the human metabotropic glutamate receptor 2.

Authors:  A Farinha; H Lavreysen; L Peeters; B Russo; S Masure; A A Trabanco; J Cid; G Tresadern
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

9.  BCL::MolAlign: Three-Dimensional Small Molecule Alignment for Pharmacophore Mapping.

Authors:  Benjamin P Brown; Jeffrey Mendenhall; Jens Meiler
Journal:  J Chem Inf Model       Date:  2019-02-12       Impact factor: 4.956

10.  Identification of Global and Ligand-Specific Calcium Sensing Receptor Activation Mechanisms.

Authors:  Andrew N Keller; Irina Kufareva; Tracy M Josephs; Jiayin Diao; Vyvyan T Mai; Arthur D Conigrave; Arthur Christopoulos; Karen J Gregory; Katie Leach
Journal:  Mol Pharmacol       Date:  2018-04-10       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.